Consensus and controversies regarding the treatment of rhabdomyosarcoma

Scott C. Borinstein; Diana Steppan; Masanori Hayashi; David M. Loeb; Michael S. Isakoff; Odion Binitie; Andrew S. Brohl; Julia A. Bridge; Mark Stavas; Eric T. Shinohara; William H. Meyer; Damon R. Reed; Lars M. Wagner

doi:10.1002/pbc.26809

Consensus and controversies regarding the treatment of rhabdomyosarcoma

Scott C. Borinstein, Diana Steppan, Masanori Hayashi, David M. Loeb, Michael S. Isakoff, Odion Binitie, Andrew S. Brohl, Julia A. Bridge, Mark Stavas, Eric T. Shinohara, William H. Meyer, Damon R. Reed, Lars M. Wagner

Research output: Contribution to journal › Review article › peer-review

71 Scopus citations

Abstract

Optimal treatment of rhabdomyosarcoma (RMS) requires multidisciplinary approach, incorporating chemotherapy with local control. Although current therapies are built on cooperative group trials, a comprehensive standard of care to guide clinical decision making has been lacking, especially for relapsed patients. Therefore, we assembled a panel of pediatric and adolescent and young adult sarcoma experts to develop treatment guidelines for managing RMS and to identify areas in which further research is needed. We created algorithms incorporating evidence-based care for patients with RMS, emphasizing the importance of clinical trials and close integration of all specialties involved in the care of these patients.

Original language	English (US)
Article number	e26809
Journal	Pediatric Blood and Cancer
Volume	65
Issue number	2
DOIs	https://doi.org/10.1002/pbc.26809
State	Published - Feb 2018

Keywords

adolescent and young adult
chemotherapy
pediatric
rhabdomyosarcoma
sarcoma

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.26809

Cite this

@article{5bb08da8e7d4430a8010589f67697dfa,

title = "Consensus and controversies regarding the treatment of rhabdomyosarcoma",

abstract = "Optimal treatment of rhabdomyosarcoma (RMS) requires multidisciplinary approach, incorporating chemotherapy with local control. Although current therapies are built on cooperative group trials, a comprehensive standard of care to guide clinical decision making has been lacking, especially for relapsed patients. Therefore, we assembled a panel of pediatric and adolescent and young adult sarcoma experts to develop treatment guidelines for managing RMS and to identify areas in which further research is needed. We created algorithms incorporating evidence-based care for patients with RMS, emphasizing the importance of clinical trials and close integration of all specialties involved in the care of these patients.",

keywords = "adolescent and young adult, chemotherapy, pediatric, rhabdomyosarcoma, sarcoma",

author = "Borinstein, {Scott C.} and Diana Steppan and Masanori Hayashi and Loeb, {David M.} and Isakoff, {Michael S.} and Odion Binitie and Brohl, {Andrew S.} and Bridge, {Julia A.} and Mark Stavas and Shinohara, {Eric T.} and Meyer, {William H.} and Reed, {Damon R.} and Wagner, {Lars M.}",

note = "Publisher Copyright: {\textcopyright} 2017 Wiley Periodicals, Inc.",

year = "2018",

month = feb,

doi = "10.1002/pbc.26809",

language = "English (US)",

volume = "65",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "2",

}

TY - JOUR

T1 - Consensus and controversies regarding the treatment of rhabdomyosarcoma

AU - Borinstein, Scott C.

AU - Steppan, Diana

AU - Hayashi, Masanori

AU - Loeb, David M.

AU - Isakoff, Michael S.

AU - Binitie, Odion

AU - Brohl, Andrew S.

AU - Bridge, Julia A.

AU - Stavas, Mark

AU - Shinohara, Eric T.

AU - Meyer, William H.

AU - Reed, Damon R.

AU - Wagner, Lars M.

PY - 2018/2

Y1 - 2018/2

N2 - Optimal treatment of rhabdomyosarcoma (RMS) requires multidisciplinary approach, incorporating chemotherapy with local control. Although current therapies are built on cooperative group trials, a comprehensive standard of care to guide clinical decision making has been lacking, especially for relapsed patients. Therefore, we assembled a panel of pediatric and adolescent and young adult sarcoma experts to develop treatment guidelines for managing RMS and to identify areas in which further research is needed. We created algorithms incorporating evidence-based care for patients with RMS, emphasizing the importance of clinical trials and close integration of all specialties involved in the care of these patients.

AB - Optimal treatment of rhabdomyosarcoma (RMS) requires multidisciplinary approach, incorporating chemotherapy with local control. Although current therapies are built on cooperative group trials, a comprehensive standard of care to guide clinical decision making has been lacking, especially for relapsed patients. Therefore, we assembled a panel of pediatric and adolescent and young adult sarcoma experts to develop treatment guidelines for managing RMS and to identify areas in which further research is needed. We created algorithms incorporating evidence-based care for patients with RMS, emphasizing the importance of clinical trials and close integration of all specialties involved in the care of these patients.

KW - adolescent and young adult

KW - chemotherapy

KW - pediatric

KW - rhabdomyosarcoma

KW - sarcoma

UR - http://www.scopus.com/inward/record.url?scp=85038565295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038565295&partnerID=8YFLogxK

U2 - 10.1002/pbc.26809

DO - 10.1002/pbc.26809

M3 - Review article

C2 - 28905489

AN - SCOPUS:85038565295

SN - 1545-5009

VL - 65

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 2

M1 - e26809

ER -

Consensus and controversies regarding the treatment of rhabdomyosarcoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this